p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

The KIT-inhibitor imatinib mesylate (IM) has greatly improved the treatment of metastatic gastrointestinal stromal tumors (GIST). IM exhibits strong antiproliferative effects but fails to induce sufficient levels of apoptosis resulting in low pathologic complete remission rates and a high rate of se...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Henze, Joern, Mühlenberg, Thomas, Simon, Susanne, Grabellus, Florian, Rubin, Brian, Taeger, Georg, Schuler, Martin, Treckmann, Juergen, Debiec-Rychter, Maria, Taguchi, Takahiro, Fletcher, Jonathan A., Bauer, Sebastian
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3360609/
https://ncbi.nlm.nih.gov/pubmed/22662219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0037776
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares